Celltrion: "Stock Undervalued... Reviewing Measures to Enhance Shareholder Value with Major Shareholders"

Letter to Shareholders Posted on Official Website on May 19

Celltrion announced on May 19 that it will implement measures to enhance shareholder value in response to the current situation where its stock price is undervalued relative to its fundamentals.

In a letter to shareholders posted on its official website, Celltrion stated, "The company and its major shareholders will comprehensively review a variety of measures to enhance shareholder value."

Celltrion cited external factors such as geopolitical uncertainties in the Middle East, increased volatility in international oil prices, and supply-demand imbalance in global stock markets as the reasons for its sluggish stock performance. The company explained that, as a result, the overall value of companies in the bio-pharmaceutical sector is not being fully recognized.

The company also emphasized that its own fundamentals remain solid. It reported record-high revenue in the first quarter and improved profitability. According to the company, its export-oriented business structure minimizes currency risk, and its portfolio, focused on therapeutic products, is less sensitive to economic cycles.

Celltrion stated, "We will continue to do our utmost to strengthen business competitiveness and secure a foundation for sustainable growth. We will also share our second-quarter results as promptly and transparently as possible, and continue implementing shareholder-friendly policies based on ongoing market monitoring to meet shareholder expectations."

This content was produced with the assistance of AI translation services.